META vs SURG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.
SURG exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.91, indicating negative shareholder equity. While the company shows impressive top-line revenue growth of 68.70%, it is fundamentally broken, reporting a negative gross margin of -18.59%, meaning it loses money on every dollar of revenue generated. Severe liquidity risk is evident with a current ratio of 0.38, and a consistent track record of missing earnings estimates (0/4 in the last year) suggests a complete disconnect between analyst projections and operational reality.
Compare Another Pair
Related Comparisons
META vs SURG: Head-to-Head Comparison
This page compares Meta Platforms, Inc. (META) and SurgePays, Inc. (SURG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.